anayamalik, Author at European Medical Journal - Page 61 of 83

Rethinking Disability Metrics in MS Trials

CRITICAL questions about the utility of PIRA and RAW as outcome measures in clinical trials for RRMS have been investigated in recently published research.

COVID-19 Linked to Faster Kidney Decline

A recent cohort study highlighted a link between COVID-19 infection and accelerated kidney function decline, surpassing declines observed after other respiratory infections like pneumonia.

Premature Rheumatoid Arthritis Death Surge in Native Americans

Native Americans experience the highest premature mortality rates from rheumatoid arthritis (RA) in the United States, according to a comprehensive study analyzing national data from 1999 to 2020.

Breast Cancer's Bone Marrow Spread Linked to Aggressive Traits

A recent study has unveiled a mechanism by which estrogen receptor-positive (ER+) breast cancer cells become more aggressive after spreading to the bone marrow.

Doctors and Patients Underinformed on Epilepsy Pregnancy Risks

Significant gaps in the knowledge and attitudes of healthcare providers and females with epilepsy regarding reproductive health and pregnancy have been exposed in a new study.

Frailty Progression Accelerated by Lung Impairments

COPD and preserved ratio impaired spirometry (PRISm) have been identified as key accelerators of frailty progression in older adults in a new study.

Lebrikizumab As Extended Therapy in Chronic Eczema

Patients with moderate-to-severe atopic dermatitis who did not initially meet response criteria for lebrikizumab at 16 weeks can still achieve improvements with continued therapy, according to a recent clinical trial analysis.

Pediatric Flu Vaccine: 50% Effectiveness Proven

The consistent effectiveness of influenza vaccines in protecting children from severe flu-related illnesses has been highlighted in recently published findings.

Understanding Cognitive Challenges After Chemotherapy

A recently published systematic review has shed light on chemotherapy-related cognitive impairment (CRCI) and its association with changes in brain connectivity and function.

Efficacy of Selpercatinib Beyond NSCLC Progression

Selpercatinib, a targeted RET kinase inhibitor, has demonstrated continued efficacy in treating RET fusion-positive non–small cell lung cancer (NSCLC) even after disease progression.